Amicogen Decides on 8.55 Million Share Third-Party Allotment, Raising Concerns of Dilution and Change in Control
Amicogen will issue 8,554,319 new shares via a third-party allotment to raise approximately 10 billion won for operating funds.
The issue price of 1,169 won is about 22.7% below the current market price of 1,513 won, resulting in a dilution of 12.1% of total outstanding shares.
The counterparty YK BioNova Holdings is a small entity with capital of only 10 million won and is expected to become the largest shareholder after the transaction, raising governance concerns.
All new shares are subject to a 1-year lock-up, but the substantial dilution and change in control pose risks to existing shareholders.
No treasury stock acquisition or cancellation plan was disclosed in connection with this capital increase.
The counterparty's financials as of 2025 show total assets of 10 million won and total capital of 10 million won, indicating very low financial soundness.
[AI Summary]This capital increase is negative for shareholder value due to severe dilution and a low-credibility counterparty, with proceeds used for general operating purposes rather than growth investments.
KOSDAQ Filing Information
[Correction of Description] Report on Major Events (Decision on Paid-in Capital Increase)